BioAdaptivesBDPT -18.18% Return-on-Tangible-Asset is -245.30% as of Mar. 2026. The stock has 5 warning signs investors should review. Among 1,986 Consumer Packaged Goods companies, BioAdaptives ranks worse than 99.65% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. BioAdaptives's annualizedNet Income for the quarter that ended in Mar. 2026 was $-0.44 Mil. BioAdaptives's average total tangible assets for the quarter that ended in Mar. 2026 was $0.18 Mil. Therefore, BioAdaptives's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -245.30%.
The historical rank and industry rank for BioAdaptives's Return-on-Tangible-Asset or its related term are showing as below:
BDPT'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -3939.53 Med: -1307.32 Max: -356.72
Current: -846.95
During the past 11 years, BioAdaptives's highest Return-on-Tangible-Asset was -356.72%. The lowest was -3939.53%. And the median was -1307.32%.
BDPT's Return-on-Tangible-Asset is ranked worse than 99.65% of 1986
companies
in the Consumer Packaged Goods industry
Industry Median: 3.38
vs BDPT: -846.95
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
BioAdaptives Return-on-Tangible-Asset Related Terms
BioAdaptives Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for BioAdaptives's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BDPT vs NBND, BSFC, MEHA: Return-on-Tangible-Asset Comparison
For the Packaged Foods subindustry, BioAdaptives's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioAdaptives Return-on-Tangible-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, BioAdaptives's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where BioAdaptives's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -245.30% mean?
BioAdaptives (BDPT) has a Return-on-Tangible-Asset of -245.30% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BioAdaptives and its competitors. According to the industry distribution chart, BioAdaptives ranks #1979 out of 1986 companies in the Consumer Packaged Goods industry, placing it in the top 99.6%.
Is BioAdaptives' Return-on-Tangible-Asset too high?
BioAdaptives' current Return-on-Tangible-Asset is -245.30%. Based on the distribution chart, BioAdaptives ranks #1979 out of 1986 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers.
How does BioAdaptives' Return-on-Tangible-Asset compare to NBND and BSFC?
According to the Consumer Packaged Goods industry distribution chart, BioAdaptives ranks #1979 out of 1986 companies for Return-on-Tangible-Asset. This places BioAdaptives in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Consumer Packaged Goods company?
The median Return-on-Tangible-Asset among Consumer Packaged Goods companies is 3.38, based on 1,986 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BioAdaptives and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Asset is 3.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioAdaptives's current Return-on-Tangible-Asset is -245.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioAdaptives stock overvalued right now?
BioAdaptives (BDPT) has a current Return-on-Tangible-Asset of -245.30%. The current Return-on-Tangible-Asset is -245.30%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For BioAdaptives (BDPT), the current Return-on-Tangible-Asset is -245.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioAdaptives Inc is engaged in investigating, marketing, and distributing natural plant, algal, and cyanobacteria-based products and medical devices that enhance health and wellness for humans and animals, with a focus on nootropics, anti-aging, weight control, relaxation, pain relief, and anti-viral properties. The company's current products in development include dietary supplements utilizing natural ingredients and proprietary methods to optimize the availability of nutrients in foods and beverages. The human products are designed to aid in cognitive health, regenerative stem cell activation, and healthy weight loss. The company's products include MyndMed, Zeranovia, and Wynovia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDPT has been successfully added to your 